SIETES :: 93212 citas

Resultados de la búsqueda por DERMATOLÓGICOS REFINAR BÚSQUEDA

21.

Hammann F, Gotta V, Conen K, Medinger M, Cesana P, Rochlitz C, Taegtmeyer AB. Pharmacokinetic interaction between taxanes and amiodarone leading to severe toxicity. Br J Clin Pharmacol 2017;83:927-30. [Ref.ID 101972]

22.

Walter SR, Day RO, Gallego B, Westbrook JI. The impact of serious adverse drug reactions: a population-based study of a decade of hospital admissions in New South Wales, Australia. Br J Clin Pharmacol 2017;83:416-26. [Ref.ID 101933]

23.

Ramírez E, Medrano-Casique N, Tong HY, Bellón T, Cabañas R, Fiandor A, González-Ramos J, Herranz P, Trigo E, Muñoz M, Borobia AM, Carcas AJ, Frías J. Eosinophilic drug reactions detected by a prospective pharmacovigilance programme in a tertiary hospital. Br J Clin Pharmacol 2017;83:400-15. [Ref.ID 101932]

24.

Finch A, Kubler P. The management of gout. Australian Prescriber 2016;39:1 de agosto. [Ref.ID 100572]

25.

Anónimo. FDA approves Differin Gel 0.1% for over-the-counter use to treat acne. U.S. Food and Drug Administration 2016:8 de julio. [Ref.ID 100485]

26.

Anonimo. Zecuity (sumatriptan) migraine patch: Drug Safety Communication - FDA evaluating risk of burns and scars. FDA MedWatch alert 2016:2 de junio. [Ref.ID 100411]

27.

Anónimo. Zecuity (sumatriptan) migraine patch: Drug Safety Communication - FDA evaluating risk of burns and scars. U.S. Food and Drug Administration 2016:2 de junio. [Ref.ID 100357]

28.

Imbernón-Moya A, Chico R, Aguilar-Martínez A. Manifestaciones cutáneas y mucosas asociadas al consumo de cocaína. Med Clin (Barc) 2016;146:544-9. [Ref.ID 100354]

29.

30.

Thaçi D, Simpson EL, Beck LA, Bieber T, Blauvelt A, Papp K, Soong W, Worm M, Szepietowski JC, Sofen H, Kawashima M, Wu R, Weinstein SP, Graham NMH, Pirozzi G, Teper A, Sutherland ER, Mastey V, Stahl N, Yancopoulos GD, Ardeleanu M. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial. Lancet 2016;387:40-52. [Ref.ID 99988]

31.

Tsianakas A, Ständer S. Dupilumab: a milestone in the treatment of atopic dermatitis. Lancet 2016;387:4-5. [Ref.ID 99987]

32.

Anónimo. Vemurafenib (Zelboraf): risk of potentiation of radiation toxicity. Drug Safety Update 2015;9:2. [Ref.ID 99642]

33.

Viola E, Pittoni AC, Drahos A, Moretti U, Conforti A. Photosensitivity with angiotensin II receptor blockers: a retrospective study using data from VigiBase. Drug Saf 2015;38:889-94. [Ref.ID 99615]

34.

Yang C-Y, Chen CH, Deng S-T, Huang C-S, Lin Y-J, Chen Y-J, Wu C-Y, Hung S-L, Chung W-H. Allopurinol use and risk of fatal hypersensitivity reactions: A nationwide population-based study in Taiwan. JAMA Intern Med 2015;175:1550-7. [Ref.ID 99256]

35.

36.

Martín-Merino E, de Abajo FJ, Gil M. Risk of toxic epidermal necrolysis and Stevens-Johnson syndrome associated with benzodiazepines: a population-based cohort study. Eur J Clin Pharmacol 2015;71:759-66. [Ref.ID 99180]

37.

Barnes L, Kaya G, Rollason V. Topical corticosteroid-induced skin atrophy: a comprehensive review. Drug Saf 2015;38:493-509. [Ref.ID 99074]

38.

Anónimo. Galantamine: atteintes cutanées graves. Prescrire 2015;35:105. [Ref.ID 98914]

39.

Anónimo. Levure de riz rouge: troubles musculaires et hépatiques. Prescrire 2015;35:18. [Ref.ID 98901]

40.

Macy E, Contreras R. Adverse reactions associated with oral and parenteral use of cephalosporins: A retrospective population-based analysis. J Allergy Clin Immunol 2015;135:745-52. [Ref.ID 98852]